Afzanna 20mg Tablet

Afzanna 20mg tablet is a targeted anti-cancer medication which is highly recommended to lung cancer patients by healthcare professional. The medicine works by blocking epidermal growth factor receptor (EGFR) which is involved in the growth and multiplication of cancer cells in the body, thereby helping to slow or stop tumor progression. Medication contains Afatinib as its active ingredient which is present in its salt composition which helps to slow down the process of formation of cancer cells in the body. Strict medical guidelines must be followed during the treatment to ensure safety and effectiveness of the treatment.

Non small cell lung cancer

Afzanna 20mg tablet cause side effects in some patients and these can vary from mild to moderate depending on individual response and overall health outcomes. Discuss with doctor if the symptoms persist:
● Loss of appetite
● Abdominal pain
● Interstitial lung disease (ILD)
● Severe diarrhea or dehydration
● Liver problems
● Diarrhea
● Mouth sores
● Acne or skin rash
● Dry skin or itching
● Eye irritation or dryness
● Respiratory infections

Afzanna 20mg tablet is a prescription based medication, doctors suggest consuming the medicine on an empty stomach at the same time everyday with a whole glass of water. Never skip or double the dose, if you miss a dose take the next one at the schedule time unless your advises otherwise. Taking it in the wrong way may cause serious side effects and lead to complications.

Lung cancer is caused by epidermal growth factor receptor (EGFR) which is a primary cause of cancer cell growth and multiplication of cancer cells in the body. Afzanna tablet work by binding and inhibiting the enzyme EGFR, thereby helping to stop the growth and multiplication of cancer cells. Doctors prescribed this medication to patients whose cancer cell is driven by EGFR mutation, based on their medical condition and treatment plan.

• Wecker, H., & Waller, C. F. (2018). Afatinib. Small Molecules in Oncology, 199-215.
• Dungo, R. T., & Keating, G. M. (2013). Afatinib: first global approval. Drugs, 73(13), 1503-1515.
• Wind, S., Schnell, D., Ebner, T., Freiwald, M., & Stopfer, P. (2017). Clinical pharmacokinetics and pharmacodynamics of afatinib. Clinical pharmacokinetics, 56(3), 235-250.
• Nelson, V., Ziehr, J., Agulnik, M., & Johnson, M. (2013). Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC. OncoTargets and therapy, 135-143.
• Keating, G. M. (2014). Afatinib: a review of its use in the treatment of advanced non-small cell lung cancer. Drugs, 74(2), 207-221.